| 标题 |
378MO Efficacy and safety of disitamab vedotin (RC48) combination therapy for HER2-expressing advanced or recurrent gynecologic malignancies: a real-world retrospective study
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供,该求助的时间将会延长,查看原因?
|
| 其它 | Wang D, Li J, Lin Z, et al. 378MO Efficacy and safety of disitamab vedotin (RC48) combination therapy for HER2-expressing advanced or recurrent gynecologic malignancies: a real-world retrospective study [J]. Annals of Oncology, 2024, 35 (Suppl 11): mdae378. |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)